FDA Approves Pfizer, Moderna Covid Booster Shots

The video discusses the impact of COVID-19 booster shots on the stocks of Moderna and Pfizer. It highlights how state regulations have influenced market reactions, with Moderna being more affected due to its reliance on COVID-19 sales. The video also examines Pfizer's revenue dependency on the COVID-19 vaccine, despite its diverse business portfolio.

What was the significant news regarding COVID-19 booster shots?

• They were approved for children under 12.

• They were made available for people aged 18 and older.

• They were only available in Europe.

• They were banned in several states.

Which companies are more dependent on COVID-19 sales compared to Pfizer?

• GSK and Sanofi

• Novavax and Sinovac

• Moderna and BioNTech

• Johnson & Johnson and AstraZeneca

What financial challenge did Moderna face recently?

• Loss of key patents

• Cutting full-year revenue projections

• Increased production costs

• Decline in stock prices

What percentage of Pfizer's revenue in the latest quarter came from the COVID-19 vaccine?

• 30%

• 45%

• 75%

• 60%

What is the positive implication of selling additional COVID-19 doses for Moderna and Pfizer?

• Reduction in production costs

• Higher revenue and business growth

• Increased market competition

• Expansion into new markets